Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Predicting resistance to synthetic lethal therapies in cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Onvansertib in combination with chemotherapy and bevacizumab in second-line treatment of KRAS-mutant metastatic colorectal cancer: A single-arm, phase II trial
10.1200/jco-24-01266 · 2025 · External reference
10.1038/s41586-019-1103-9
10.1038/s41586-019-1103-9 · External reference
Predicting synthetic lethal interactions using conserved patterns in protein interaction networks
10.1371/journal.pcbi.1006888 · 2019 · External reference
10.1023/a:1010933404324
10.1023/a:1010933404324 · External reference
Generating simple random graphs with prescribed degree distribution
10.1007/s10955-006-9168-x · 2006 · External reference
10.1038/nature03443
10.1038/nature03443 · External reference
10.1016/j.cell.2010.03.012
10.1016/j.cell.2010.03.012 · External reference
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours
10.1038/s41416-023-02436-2 · 2024 · External reference
Identification of regulators of poly-ADP-ribose polymerase inhibitor response through complementary CRISPR knockout and activation screens
10.1038/s41467-020-19961-w · 2020 · External reference
A global genetic interaction network maps a wiring diagram of cellular function
10.1126/science.aaf1420 · 2016 · External reference
Comprehensive prediction of robust synthetic lethality between paralog pairs in cancer cell lines
10.1016/j.cels.2021.08.006 · 2021 · External reference
10.25452/figshare.plus.24667905.v2
10.25452/figshare.plus.24667905.v2 · External reference
10.1038/s41556-018-0140-1
10.1038/s41556-018-0140-1 · External reference
MAGICAL: A multi-class classifier to predict synthetic lethal and viable interactions using protein-protein interaction network
10.1371/journal.pcbi.1012336 · 2024 · External reference
10.1038/s41388-022-02482-9
10.1038/s41388-022-02482-9 · External reference
10.1093/nar/gkaa882
10.1093/nar/gkaa882 · External reference
10.1093/nar/gkae1071
10.1093/nar/gkae1071 · External reference
10.1158/2159-8290.cd-23-0669
10.1158/2159-8290.cd-23-0669 · External reference
10.1038/nature03445
10.1038/nature03445 · External reference
10.1038/s41586-022-04638-9
10.1038/s41586-022-04638-9 · External reference
10.1038/s41573-025-01273-7
10.1038/s41573-025-01273-7 · External reference
10.1126/science.aaz1776
10.1126/science.aaz1776 · External reference
10.1016/j.cell.2018.03.050
10.1016/j.cell.2018.03.050 · External reference
10.25080/tcwv9851
10.25080/tcwv9851 · External reference
10.1158/1535-7163.mct-14-0406
10.1158/1535-7163.mct-14-0406 · External reference
10.1038/s41586-020-2649-2
10.1038/s41586-020-2649-2 · External reference
10.1158/0008-5472.can-18-2711
10.1158/0008-5472.can-18-2711 · External reference
10.1038/nrc3599
10.1038/nrc3599 · External reference
10.1038/s41573-019-0046-z
10.1038/s41573-019-0046-z · External reference
10.1109/mcse.2007.55
10.1109/mcse.2007.55 · External reference
10.1016/j.cell.2016.06.017
10.1016/j.cell.2016.06.017 · External reference
10.1158/2159-8290.cd-12-0049
10.1158/2159-8290.cd-12-0049 · External reference
10.1038/nbt1096
10.1038/nbt1096 · External reference
10.1158/0008-5472.can-25-1464
10.1158/0008-5472.can-25-1464 · External reference
10.7554/elife.18970
10.7554/elife.18970 · External reference
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science (New York
10.1126/science.aad5214 · 2016 · External reference
10.1126/science.aao1729
10.1126/science.aao1729 · External reference
PARP inhibitor resistance: the underlying mechanisms and clinical implications
10.1186/s12943-020-01227-0 · 2020 · External reference
SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
10.1158/0008-5472.can-21-4339 · 2022 · External reference
10.1093/nar/gkab628
10.1093/nar/gkab628 · External reference
10.7554/elife.58925
10.7554/elife.58925 · External reference
MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis
10.1016/j.celrep.2016.03.043 · 2016 · External reference
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5
10.1126/science.aad5944 · 2016 · External reference
Ovarian cancers harbor defects in nonhomologous end joining resulting in resistance to rucaparib
10.1158/1078-0432.ccr-16-0564 · 2017 · External reference
10.1016/j.cell.2017.07.005
10.1016/j.cell.2017.07.005 · External reference
10.25080/majora-92bf1922-00a
10.25080/majora-92bf1922-00a · External reference
10.1158/1541-7786.mcr-14-0240
10.1158/1541-7786.mcr-14-0240 · External reference
10.1038/ng.3984
10.1038/ng.3984 · External reference
10.1002/rsa.3240060204
10.1002/rsa.3240060204 · External reference
10.1074/jbc.ra118.004028
10.1074/jbc.ra118.004028 · External reference
10.1038/s41586-018-0340-7
10.1038/s41586-018-0340-7 · External reference
Abstract P2-07-24: Results from the phase II study of ROS1 Targeting with crizotinib in advanced E-cadherin Negative Lobular Breast Cancer (ROLo)
10.1158/1557-3265.sabcs24-p2-07-24 · 2025 · External reference
10.1002/pro.3978
10.1002/pro.3978 · External reference
10.48550/arxiv.1201.0490
10.48550/arxiv.1201.0490 · External reference
Selective killing of ATM-or p53-deficient cancer cells through inhibition of ATR
10.1038/nchembio.573 · 2011 · External reference
10.1016/j.annonc.2024.08.2339
10.1016/j.annonc.2024.08.2339 · External reference
10.1016/j.cell.2014.10.050
10.1016/j.cell.2014.10.050 · External reference
10.1038/s41588-023-01557-x
10.1038/s41588-023-01557-x · External reference
A systematic analysis of the landscape of synthetic lethality-driven precision oncology
10.1016/j.medj.2023.12.009 · 2024 · External reference
10.1158/0008-5472.can-16-3398
10.1158/0008-5472.can-16-3398 · External reference
10.1093/nar/gkac888
10.1093/nar/gkac888 · External reference
Genome-scale CRISPR-Cas9 knockout screening in human cells. Science (New York
10.1126/science.1247005 · 2014 · External reference
10.1101/gr.1239303
10.1101/gr.1239303 · External reference
Characterization of TNG348: A selective, allosteric USP1 inhibitor that synergizes with PARP inhibitors in tumors with homologous recombination deficiency
10.1158/1535-7163.mct-24-0515 · 2025 · External reference
10.1186/1471-2164-10-22
10.1186/1471-2164-10-22 · External reference
Next-generation diagnostics and disease-gene discovery with the Exomiser
10.1038/nprot.2015.124 · 2015 · External reference
10.1038/s41568-018-0060-1
10.1038/s41568-018-0060-1 · External reference
10.1093/nar/gkac1000
10.1093/nar/gkac1000 · External reference
A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations
10.1038/nsmb.2076 · 2011 · External reference
10.1158/2159-8290.cd-13-0617
10.1158/2159-8290.cd-13-0617 · External reference
10.1038/s41592-019-0686-2
10.1038/s41592-019-0686-2 · External reference
10.1158/2159-8290.cd-13-0631
10.1158/2159-8290.cd-13-0631 · External reference
ATXN1L, CIC, and ETS transcription factors modulate sensitivity to MAPK pathway inhibition
10.1016/j.celrep.2017.01.031 · 2017 · External reference
10.1073/pnas.0802655105
10.1073/pnas.0802655105 · External reference
10.1098/rsob.220118
10.1098/rsob.220118 · External reference
PRMT5 confers lipid metabolism reprogramming, tumour growth and metastasis depending on the SIRT7-mediated desuccinylation of PRMT5 K387 in tumours
10.1038/s41401-021-00841-y · 2022 · External reference
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
10.1038/s41467-021-23463-8 · 2021 · External reference
Genome-wide CRISPR/Cas9 screening for drug resistance in tumors
10.3389/fphar.2023.1284610 · 2023 · External reference
